Oklahoma Administrative Code
Title 310 - Oklahoma State Department of Health
Chapter 550 - Newborn Screening and resources for trisomy 13, 18, and 21
Subchapter 19 - Newborn Screening Reporting
Section 310:550-19-1 - Physician Reporting and Medical Records

Universal Citation: OK Admin Code 310:550-19-1

Current through Vol. 42, No. 1, September 16, 2024

(a) If confirmatory or follow-up testing is not performed by the Newborn Screening Laboratory or through a contract laboratory designated by the Newborn Screening Program, the infant's physician must report to the Newborn Screening Program Coordinator the results within 7 days after the completion of the medical evaluation, using the Department's Newborn Screening Report Form as illustrated in Appendix B of this Chapter. A copy of the confirmatory test results must accompany the report form.

(b) For all diagnosed cases of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders , and upon completion of laboratory validation studies and establishment of short-term follow-up services, Severe Combined Immunodeficiency (SCID) detectable via the Department's laboratory technology utilized in newborn screening and approved by the Commissioner of Health, the infant's physician shall report treatment date if applicable, and referral information to the Newborn Screening Program Coordinator by completing the Department's Newborn Screening Report Form as illustrated in Appendix B of this Chapter.

(c) These reports shall be confidential and may be utilized only for the purpose of ensuring service delivery, program administration, data analysis, and evaluation.

(d) On request, a birthing facility or health care provider shall make available to the OSDH NBS Program or Oklahoma Birth Defects Registry:

(1) Medical records;

(2) Records of laboratory test; and

(3) Any other medical information considered necessary to:
(A) Determine final outcomes of abnormal CCHD screening results; and

(B) Evaluate CCHD screening activities in the State; including:
(i) Performance of follow-up evaluations and diagnostic tests;

(ii) Initiation of treatment when necessary; and

(iii) Surveillance of the accuracy and efficacy of the screening.

(e) Information that the Department receives under this chapter is confidential and may only be used or disclosed:

(1) To provide services to the newborn infant and the infant's family;

(2) To study the relationships of the various factors determining the frequency and distribution of CCHD;

(3) For State or federally mandated statistical reports; and

(4) To ensure that the information received by the Department is accurate and reliable.

Amended at 8 Ok Reg 3115, eff 7-12-91 (emergency); Amended at 9 Ok Reg 1475, eff 5-1-92; Amended at 12 Ok Reg 41, eff 10-5-94 (emergency); Amended at 12 Ok Reg 1685, eff 6-12-95; Amended at 15 Ok Reg 121, eff 10-15-97 (emergency); Amended at 15 Ok Reg 1979, eff 5-26-98; Amended at 21 Ok Reg 1286, eff 5-27-04; Amended at 25 Ok Reg 105, eff 10-2-07 (emergency); Amended at 25 Ok Reg 1153, eff 5-25-08

Disclaimer: These regulations may not be the most recent version. Oklahoma may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.